This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXNPEC0K08U_M.jpg
Orbimed Advisors’s holding in Oric Pharmaceuticals, Inc. decreased to about 2.5 million shares with the transaction.
Orbimed Advisors first bought Oric Pharmaceuticals, Inc. stock in the second quarter of 2020.
Orbimed Advisors also owns Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), Biogen Inc (NASDAQ:BIIB), Neurocrine Biosciences Inc (NASDAQ:NBIX) and Theravance Biopharma, Inc. (NASDAQ:TBPH).
Oric Pharmaceuticals, Inc. is its number fifteen position by number of shares and market value among pharmaceuticals stocks.
In contrast, Alkeon Capital Management, California State Teachers Retirement System, and Citigroup (NYSE:C) added to ORIC shares.
